阿尔法2 - 宏球蛋白多态性和对阿尔茨海默病的敏感性:基于62项研究的综合元分析
Hongwei Zhang1,2, Da Liu1,2, Yuanyuan Duan3
1Department of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, China.
Journal of Alzheimer's disease reports
|December 25, 2023
概括
这次元分析发现,某些α2-宏球蛋白 (A2M) 基因变异与特定人群中的阿尔茨海默病 (AD) 风险有关. 需要进一步的研究来确认A2M和AD的这些关联.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 医学研究 医学研究
背景情况:
- 已经研究了α2-宏球蛋白 (A2M) 基因与阿尔茨海默病 (AD) 之间的联系,但在不同的人群中发现的结果是不一致的.
- 这项研究解决了对A2M基因与AD风险相关性的全面评估的需求.
结论:
- 阿尔法2-宏球蛋白 (A2M) 单核酸多态 (SNPs) 可能会影响特定亚群体内的阿尔茨海默病风险.
- 建议进行更大规模的研究来验证这些发现,并进一步阐明A2M-AD关系.
关键词:
A2M A2M A2M A2M A2M A2M A2M A2M阿尔法2-巨型球蛋白阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.国家统一计划 (SNP) 是一个国家统一计划.进行元分析.系统性审查 系统性审查更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.9K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
相关概念视频
01:26Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195